# EDGAR Filing Document

**Accession Number:** 0000897448
**File Stem:** 0001193125-26-036165
**Filing Date:** 2026-2
**Character Count:** 9050
**Document Hash:** 2f49cc8b8a6838d6a244297ac55174e8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-036165.hdr.sgml**: 20260203

**ACCESSION NUMBER**: 0001193125-26-036165

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260131

**FILED AS OF DATE**: 20260203

**DATE AS OF CHANGE**: 20260203

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Fishman Peter L.
- **CENTRAL INDEX KEY:** 0002042862

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-21392
- **FILM NUMBER:** 26595291

**MAIL ADDRESS:**
- **STREET 1:** 440 RT 22
- **CITY:** BRIDGEWATER
- **STATE:** NJ
- **ZIP:** 08807
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AMARIN CORP PLC\UK
- **CENTRAL INDEX KEY:** 0000897448
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** SPACES SOUTH DOCKLANDS, BLOCK C
- **STREET 2:** 77 SIR JOHN ROGERSON'S QUAY
- **CITY:** DUBLIN 2
- **PROVINCE COUNTRY:** L2
- **BUSINESS PHONE:** 353 1 6699 020

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** SPACES SOUTH DOCKLANDS, BLOCK C
- **STREET 2:** 77 SIR JOHN ROGERSON'S QUAY
- **CITY:** DUBLIN 2
- **PROVINCE COUNTRY:** L2

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AMARIN PHARMACEUTICALS PLC
- **DATE OF NAME CHANGE:** 20000201

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ETHICAL HOLDINGS PLC
- **DATE OF NAME CHANGE:** 19930322

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Fishman Peter L.<br><sub>(Last) (First) (Middle)</sub><br>C/O AMARIN PHARMA, INC.<br>440 US HIGHWAY 22<br><sub>(Street)</sub><br>BRIDGEWATER, NJ 08807<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-01-31 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_SVP, CFO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>AMARIN CORP PLC\UK [ AMRN ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| American Depositary Shares<sup>(1)</sup> | 2026-01-31 |  | M<sup>(2)</sup> |  | 563<sup>(1)</sup> | A | <sup>(3)</sup> | 5642<sup>(1)</sup> | D |  |
| American Depositary Shares<sup>(1)</sup> | 2026-01-31 |  | F<sup>(4)</sup> |  | 310<sup>(1)</sup> | D | $15.42 | 5332<sup>(1)</sup> | D |  |
| American Depositary Shares<sup>(1)</sup> | 2026-01-31 |  | M<sup>(5)</sup> |  | 1833<sup>(1)</sup> | A | <sup>(3)</sup> | 7165<sup>(1)</sup> | D |  |
| American Depositary Shares<sup>(1)</sup> | 2026-01-31 |  | F<sup>(4)</sup> |  | 1008<sup>(1)</sup> | D | $15.42 | 6157<sup>(1)</sup> | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Restricted Stock Unit<sup>(6)</sup> | $0 | 2026-01-31 |  | M |  | 563<sup>(1)</sup> |  | <sup>(2)</sup> | <sup>(3)</sup> | American Depositary Shares<sup>(1)</sup> | 563<sup>(1)</sup> | $0.00 | 0<sup>(1)</sup> | D |  |
| Restricted Stock Unit<sup>(6)</sup> | $0 | 2026-01-31 |  | M |  | 1833<sup>(1)</sup> |  | <sup>(5)</sup> | <sup>(3)</sup> | American Depositary Shares<sup>(1)</sup> | 1833<sup>(1)</sup> | $0.00 | 1833<sup>(1)</sup> | D |  |
| Restricted Stock Unit<sup>(6)</sup> | $0 | 2026-02-01 |  | A |  | 6167<sup>(1)</sup> |  | <sup>(7)</sup> | <sup>(3)</sup> | American Depositary Shares<sup>(1)</sup> | 6167<sup>(1)</sup> | $0.00 | 6167<sup>(1)</sup> | D |  |
| Stock Option (right to buy) | $14.99 | 2026-02-01 |  | A |  | 27750<sup>(1)</sup> |  | <sup>(8)</sup> | 2036-02-01 | American Depositary Shares<sup>(1)</sup> | 27750<sup>(1)</sup> | $0.00 | 27750<sup>(1)</sup> | D |  |

---

### Footnotes:

(1) Effective April 11, 2025, the Issuer implemented a ratio change that one (1) American Depositary Share ("ADS") currently represents twenty (20) Ordinary Shares ("ADS Ratio Change"). Proportionate adjustments were made to the Issuer's outstanding equity awards. The amount of securities reported on this Form 4 reflect the ADS Ratio Change.

(2) On February 1, 2023, the Reporting Person was granted 1,690 Restricted Stock Units ("RSUs") under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). These RSUs vest in three equal installments on each of January 31, 2024, January 31, 2025, and January 31, 2026.

(3) Not applicable.

(4) Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities.

(5) On February 1, 2024, the Reporting Person was granted 5,500 RSUs under the Amarin Corporation plc 2011 Stock Incentive Plan (the "Plan"). These RSUs vest in three equal installments on each of January 31, 2025, January 31, 2026, and January 31, 2027.

(6) Each RSU represents a contingent right to receive twenty Ordinary Shares or cash in lieu thereof at the Issuer's discretion.

(7) On February 1, 2026, the Reporting Person was granted 6,167 RSUs under the Plan. These RSUs vest in three equal installments on each of January 31, 2027, January 31, 2028 and January 31, 2029.

(8) On February 1, 2026, the Reporting Person was granted an option to purchase 27,750 ADSs under the Plan. The shares subject to this option shall vest and become exercisable over three years, with 33% to vest on the first anniversary of the grant date and the balance to vest ratably over the subsequent 8 calendar quarters on the first day of each May, August, November and February.

**Signature:** /s/ Jonathan Provoost, by power of attorney  
**Date:** 2026-02-03

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**